Fantastic! Excellent explanations and very accessible. Beautifully done.

Points briefly explained in video 1) Whole genome/whole Exome/ Targeted sequencing 2) coverage 3) VAF 4) Clinical significance

Not really clear why VAF measure is dependent on tumor heterogeneity .. But seems to me this could be side-stepped by single cell sequencing? If so, single cell = less requirement for deep sequencing? And you can deploy NGS capability to broader but shallower coverage (as opposed to smaller target but deeper) .. and change the trade off between VAF sensitivity and breadth ?

I did not get where 80%, 60% is are from 15:56. Why so sure of heterogeneous?

Superb